このエントリーをはてなブックマークに追加
ID 49065
フルテキストURL
著者
Sugiura, Yuko Okayama Univ
Soga, Yoshihiko Okayama Univ
Tanimoto, Ichiro Okayama Univ
Kokeguchi, Susumu Okayama Univ
Nishide, Sachiko Okayama Univ Hosp
Kono, Kotoe Okayama Univ Hosp
Takahashi, Kanayo Okayama Univ Hosp
Fujii, Nobuharu Okayama Univ
Ishimaru, Fumihiko Okayama Univ
Tanimoto, Mitsune Okayama Univ
Yamabe, Kokoro Okayama Univ
Tsutani, Soichiro Okayama Univ
Nishimura, Fusanori Okayama Univ
Takashiba, Shogo Okayama Univ
抄録
Goals The commercially available saliva substitute Oralbalance (R) has been reported to alleviate symptoms of post-radiotherapy xerostomia in head and neck cancer patients. Oralbalance (R) may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are severely compromised, and saliva substitute must therefore not promote infection. This study was performed to determine the effects of Oralbalance (R) on microbial species identified during HCT. Patients and methods Microbial identification of oral mucosa was performed in 28 patients undergoing HCT. The antimicrobial effects of Oralbalance (R) against bacteria and fungi detected in the HCT period were examined in vitro. Briefly, bacteria and fungi were spread on agar plates, and 0.1g of Oralbalance (R) gel was applied (about phi 1cm). After incubation at 37 degrees C for 24h, the presence of a transparent zone of inhibition around Oralbalance (R) was observed. Main results Not only bacterial species constituting normal flora of the oral mucosa but also those not usually constituting normal flora, e.g., coagulase-negative Staphylococcus, were detected. A transparent zone was observed around Oralbalance (R) in all bacterial species examined. No transparent zone was observed for Candida albicans, but growth was inhibited in the area where Oralbalance (R) was applied. Conclusions Oralbalance (R) does not facilitate increases in microorganisms in the HCT period. Oral care with Oralbalance (R) does not promote infection in patients undergoing HCT.
キーワード
Hematopoietic cell transplantation
Xerostomia
Saliva substitute
Antimicrobial activity
発行日
2008-04
出版物タイトル
Supportive Care in Cancer
16巻
4号
開始ページ
421
終了ページ
424
ISSN
0941-4355
資料タイプ
学術雑誌論文
オフィシャル URL
http://dx.doi.org/ 10.1007/s00520-007-0391-z
言語
English
OAI-PMH Set
岡山大学
論文のバージョン
author
査読
有り
DOI
PubMed ID
Web of Sience KeyUT